Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination
Clicks: 102
ID: 281596
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.3
/100
102 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #119 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Immune checkpoint therapy is one of the most promising immunotherapeutic
methods that are likely able to give rise to durable treatment response for
various cancer types. Despite much progress in the past decade, there are still
critical open questions with particular regards to quantifying and predicting
the efficacy of treatment and potential optimal regimens for combining
different immune-checkpoint blockades. To shed light on this issue, here we
develop clinically-relevant, dynamical systems models of cancer immunotherapy
with a focus on the immune checkpoint PD-1/PD-L1 blockades. Our model allows
the acquisition of adaptive immune resistance in the absence of treatment,
whereas immune checkpoint blockades can reverse such resistance and boost
anti-tumor activities of effector cells. Our numerical analysis predicts that
anti-PD-1 agents are commonly less effective than anti-PD-L1 agents for a wide
range of model parameters. We also observe that combination treatment of
anti-PD-1 and anti-PD-L1 blockades leads to a desirable synergistic effect. Our
modeling framework lays the ground for future data-driven analysis on
combination therapeutics of immune-checkpoint treatment regimes and thorough
investigation of optimized treatment on a patient-by-patient basis.
| Reference Key |
fu2021immune
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kamran Kaveh; Feng Fu |
| Journal | arXiv |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.